PBIO

SOUTH EASTON, MA / ACCESSWIRE / June 30, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide food and beverage, biotherapeutics, and personal wellness industries, among others, today announced the Company’s participation in the June 30^th Revolutionizing the Development of Plant-Based Food Products webinar, sponsored by FORCE Family Office. This real-time, interactive “Presentation/Q&A Event” will cover the three pressure-based technology platforms of Pressure BioSciences, Inc., (PCT, BaroFold, UST™) with strong focus and emphasis on PBIO’s Ultra Shear Technology™ (UST) platform. UST is a revolutionary technology platform that can process oil and water into highly stable and water-soluble nanoemulsions, which in turn are expected to significantly increase the bioavailability of the active ingredient contained in the oil.

The quest for finding alternative beverages that are healthier and environmentally sustainable but also appealing to the palate – such as plant protein-based drinks – is a rapidly growing market estimated to reach $41B by 2027 (MDC Market Report). A recent study published by The Ohio State University illuminated the unique capabilities of PBIO’s UST platform for optimal formulation and processing of new and existing plant-based beverages. This presents enormous potential for PBIO…but how is the Company planning to take advantage of this remarkable opportunity. Attend and find out.

DATE: Thursday, June 30, 2022 (Noon ET)
PRESENTATION: Video Webcast
REGISTER: Click Here to Register for the June 30 FORCE Webinar

Panelists.

• Pressure BioSciences, Inc. (OTCQB: PBIO) announced on Wednesday, June 29^th the initial distribution contract and roll-out time-table for the release of the Company’s revolutionary Ultra Shear Technology™ (UST™) platform for the preparation of water soluble, long-term stable, highly bioavailable nanoemulsions of oil and water (e.g., CBD oil and water). Mr. Richard T. Schumacher, Founder and CEO, will be a panel participant. Joining Ric will be Dr. Alexander Lazarev, PBIO’s Chief Science Officer.
• FORCE Family Office is the largest network of family offices in the United States. CEO Steven Saltzstein will be the Moderator of the webinar.

Selected Recent Key Announcements – PBIO

• PBIO Announces Commercial Release of the UST Platform with Contracted Launch for Estimated $3M of UST-Processed, Nanoemulsified CBD Spray for Oral Use
• Ohio State Data Illuminate Unique Capabilities of UST Platform for Optimal Formulation and Processing of New and Existing Plant Protein-Based Beverages
• PBIO Announces Early Access Program for UST Nanoemulsion Processing

About FORCE Family Office
FORCE is the largest network of family offices in the United States with a substantial and growing presence internationally. In 2020 alone, they hosted more than 160 events, a number they expect to exceed each year going forward. Their team is dedicated to helping family offices efficiently and successfully connect with private and public companies for co-investment, research, education, and philanthropy.

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.

SOURCE: Pressure BioSciences Inc.

Safer Medical of Montana, a Seasoned Distributor of Wellness Products with a Focus on Veterans, Partners with PBI as Exclusive Distributor for Highly Stable and Water-Soluble CBD Oral Aerosol Product

SOUTH EASTON, MA / ACCESSWIRE / June 29, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agrochem, and food/beverage industries, today announced its signed agreement with Safer Medical of Montana (“SMM”) on production, distribution, commercial roll-out and financial partnership for a novel, effectively water-soluble, nanoemulsified CBD spray for oral use. SMM’s roll-out and distribution plan targets revenues of $3M or more over the first 12-months post-release. Under the agreement, PBI expects to realize more than $1M in revenues from this $3M product sales target. This is the first commercial product being produced and marketed that incorporates the Company’s patented Ultra Shear Technology™ (UST™) platform.

As announced last month, PBI and SMM have collaborated over the past year in the development of a proprietary formulation for this unique product. The companies have now completed formulation development and are securing the necessary approvals for production in the Commonwealth of Massachusetts and distribution throughout all of the United States. SMM’s initial product will be an oral spray containing 40mg/mL of nanoemulsified CBD. The companies plan to release the new CBD oral spray product to consumers during the third quarter of 2022.

Mr. John B. Hollister, Director of Sales and Marketing at PBI, observed: “This SMM agreement launches an exciting new chapter in the evolution of PBI. Building on our deep expertise in the safe applications of high-pressure technology, we are now preparing to release the first product prepared by UST – our truly revolutionary platform technology that shears oil-water emulsions down to extremely low and tightly-controlled nano-sized oil droplets. The commercialization of UST throws open the door to countless applications in diverse multi-billion-dollar markets where effective water-solubility of oil-based active ingredients is critical for optimized bioavailability and absorption – including cannabinoids, nutraceuticals, cosmetics, pharmaceuticals, food and beverages, agrochem, industrial lubricants, paints, and more.”

Mr. Hollister continued: “The feedback we have received across many sample products created with UST has exceeded all expectations. The application of UST to provide greatly improved delivery and functionality of oil-based active materials and products via nanoemulsification offers enormous potential to translate into a diverse array of major commercial opportunities for our partners and for PBI, while benefitting and redefining product expectations for consumers worldwide.”

Captain George Ackerson, Founder and CEO of SMM, shared his plans: “With this partnership and distribution agreement in place, our mission is now on the successful launch of the nanoemulsified CBD oral spray. This launch includes a key focus on accessing U.S. veterans, a group we believe will benefit greatly from this innovative product. We are reaching out to the Veterans Administration and developing plans to work with the not-for-profit Veteran Seal Team, Inc. (“VST”). In addition to direct sales through our website, we are setting up distribution with a network of nurses who specialize in the needs of veterans.”

Captain Ackerson continued: “SMM has been distributing wellness products for many years, giving us significant experience in the best ways to get novel, breakthrough products into the hands of consumers. The PBI partnership is built upon estimated first-year sales of over $3 million dollars, to be achieved through three planned phases of roll-out at increasing scale. With our current and planned distribution channels, we believe this goal is more than attainable.”

Mr. Richard T. Schumacher, President and CEO of PBI, summed up: “This first UST commercialization and partnering agreement with Captain Ackerson and Safer Medical of Montana is a pivotal transition moment in the history of PBI. We are expecting to announce significant additional agreements in the very near future, specifically in markets with an expected quick ramp to revenue, such as cosmetics, agrochem, and nutraceuticals. We also believe that our co-leadership role in the Food Industry Consortium with partner The Ohio State University, whose mission is to introduce the UST platform to food and beverage companies worldwide, will soon result in additional revenue-generating agreements. We expect that the substantial revenue expected from these future agreements will accelerate balance sheet improvements and help finance PBI’s operations, investments, growth, and trajectory to profitability before the end of 2023.”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.

Press Contacts:

Richard T. Schumacher, President & CEO (508) 230-1828 (T)
John B. Hollister, Director of Sales and Marketing (805) 908-5719 (T)
Jeffrey N. Peterson, Chairman (650)703-8557 (T)

SOURCE: Pressure BioSciences Inc.

Recent Study Published by The Ohio State University Illuminates Unique Capabilities of PBI’s UST Platform for Optimal Formulation and Processing of New and Existing Plant Protein-based Beverages

SOUTH EASTON, MA / ACCESSWIRE / June 14, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and process development services to the worldwide food and beverage, biotherapeutics, and personal wellness industries, among others, today announced a pivotal peer-reviewed scientific publication highlighting the use of PBI’s patented Ultra Shear Technology™ (“UST™”) platform in the production of protein-enriched milk containing a novel emulsified plant-protein suspension. J.J. Janahar, et al., from The Ohio State University (“Ohio State”) College of Food, Agricultural, and Environmental Sciences (“CFAES”) in a study published in the high impact journal Food Hydrocolloids, Volume 131, reported that UST successfully created stable suspensions of milk-pea protein blends in microscopic particle sizes – the objective required for commercially-suitable products, and a significant achievement that could not be reached through existing high-pressure processing (HPP) or thermal processing techniques alone.

Efforts to produce satisfying, nutritionally-efficient and sustainable food options are driving one of the fastest growing food and beverage markets worldwide. Creating cost-effective and sustainable food alternatives that appeal to the expectations and preferences of global consumers has pushed researchers to examine many alternative protein enrichment sources, including the use of almonds, oats, soy, coconuts, peas, etc. Unfortunately, many of these protein sources lack the creaminess, texture, sweetness, or other attributes that drive consumer acceptance. The blending of plant and dairy components to achieve the desired consumer appeal presents enormous market opportunities. Pea protein is of particular interest because of its high nutritional value and low cost – but it is highly insoluble in water and thus has been minimally used in protein drinks to date. PBI’s proprietary UST platform combines very high pressure and precisely controlled extreme shear forces to provide food scientists the toolset needed to successfully blend dairy and pea protein (two products which naturally resist mixing) into a sensory-appealing, nutritional, and long-term stable plant protein-based beverage.

PBI and Ohio State are co-leading a Food Industry Consortium whose mission is to introduce worldwide food and beverage companies to PBI’s UST platform for the production of higher quality, longer shelf-life, and safer liquid foods and beverages. PBI’s UST platform is the critical tool that enables and achieves targeted reductions and dependency on chemical additives or damaging heat relied upon in current processing methods. UST is pivotal in enabling the production of natural, organic, healthier, more nutritious, “clean-label” products that offer greater appeal to modern consumers.

Mr. John B. Hollister, Director of Marketing and Sales expanded: “Ohio State and PBI have initiated an aggressive outreach program to a number of preeminent food & beverage companies globally and expect to welcome many Consortium members during the second half of 2022. Members will help direct and focus Ohio State and PBI efforts across a diverse universe of prospective liquid food and beverage products, with emphasis on microbiology, stability, nutrition, sensory qualities, and increased bioavailability. UST applications development will also extend into nutraceutical products, such as infused water, functional sports beverages, and other health-focused products of high interest to consumers and producers.” (North Equities Video Interview – Hollister).

Mr. Hollister continued: “With the recent publication of the Ohio State data, an additional and very exciting application of interest is plant protein-based beverages. As new and commercially-relevant UST applications continue to be demonstrated, and Consortium members utilize their first rights to license UST for their own use, Ohio State and PBI will both benefit from resulting royalty streams. PBI will also benefit from equipment leases and consumables sales.”

Dr. Edmund Y. Ting, Senior VP of Engineering at PBI, and a pioneer in the development of high pressure-based food technologies, commented: “Many beverage ingredients that are beneficial to convenience, health, and desired sensory characteristics are not soluble in water, e.g., pea proteins. However, UST’s ability to achieve micro/nano particle size suspensions of such plant proteins offers enticing solutions for the use of these essential, water-insoluble ingredients. Interestingly, such UST-processed suspensions can be optimized to provide thickening viscosity for certain products, which can result in improved stability, nutritional value, and consumer appeal. Thus, UST’s ability to formulate complex micro/nano emulsions and suspensions will give manufacturers multiple additional options for health and wellness products. While we have previously demonstrated that UST makes fantastic nanoemulsions, there are even more applications where microemulsions as well as nano/micro suspensions are practical and useful for products and product concentrates.”

Mr. Richard T. Schumacher, President and CEO of PBI, summarized: “The quest for finding alternative beverages that are healthier and environmentally sustainable but also appealing to the palate – such as plant protein-based drinks – is a rapidly growing market estimated to reach $41B by 2027 (MDC Market Report). We are currently in discussions with industry leaders in this market, as well as companies that want to use UST to make high quality nanoemulsions to add vitamins, antioxidants, nutraceuticals, etc. to their beverages. The recent Ohio State results on UST-processed micro/nano plant protein milk suspensions, as well as previously released data om UST-enhanced nanoemulsions, support our confidence that UST has the potential to become an essential tool in future beverage development, as well as in other health-related and consumer markets (TechTalks Video). We continue to look forward to the planned Q3/Q4 2022 commercial release of the UST platform.”

Sponsorship of UST development by the U.S. Department of Agriculture’s NIFA program is deeply appreciated.

PBI’s June 30th Webinar Participation

On June 30^th at noon, PBI will participate as an invited panelist in a FORCE Family Office Webinar. Mr. Schumacher will represent PBI. Other panelists are also being invited. The Webinar will be sponsored by FORCE Family Office and will be moderated by Mr. Steven Saltzstein, CEO of FORCE. As further information becomes available, it will be placed on the Force Family Office and Pressure BioSciences websites. If you would like to receive an invitation, please contact us directly.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter

Press Contacts:

Mr. Richard T. Schumacher, President & CEO (508) 230-1828 (T)
Mr. John B. Hollister, Director Sales and Marketing (508) 230-1829 (F)
Dr. Edmund Y. Ting, Senior VP of Engineering

SOURCE: Pressure BioSciences Inc.

Phoenix, June 1, 2022 (Newsfile Corp.) — The Stock Day Podcast recently welcomed Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or “the Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services for the worldwide life sciences markets and other industries. CEO of the Company, Mr. Richard T. Schumacher, joined Stock Day host Mr. Sever Copley.

Mr. Copley began: “As an introduction, please tell us about PBI.”

“Pressure BioSciences is a highly innovative company,” explained Mr. Schumacher. “We have learned how to harness and safely use extreme pressures with exquisite precision, applying its transformative powers that move at the speed of sound in a number of areas. It is a gentle giant that accomplishes many things in the scientific laboratory or in various commercial industries, for which we currently rely on aggressive or damaging heat, cold, and chemicals to accomplish.”  He continued: “Our high-pressure breakthrough applications range from preparation of all manner of samples for scientific analysis, to the manufacture and preparation of biopharmaceuticals optimized for effectiveness, to our newest technology platform Ultra Shear Technology™(“UST™”) for the preparation of nanoemulsions and shelf stable products that have historically been beyond commercial reach.”

Mr. Copley inquired further: “We have certainly been hearing and want to learn more about the successful launch of your UST Early Access Program. Please explain!”

“UST, our latest platform technology innovation, is now being introduced into its first commercial applications.  UST puts oil and water emulsions under extremely high pressures, which drive the emulsions through a dynamically controlled valve with a nano-gap orifice to produce intense and precise shearing down to vanishingly small nanoemulsion oil droplet sizes,” said Mr. Schumacher. “We have seven UST issued patents so far, including two in the United States, with many more expected to follow.”

Mr. Schumacher continued: “The oil in these emulsions typically contains the valuable active ingredients, which could be a pharmaceutical or a nutraceutical, a functional cosmetic ingredient, or important food and beverage nutrients.  And in UST-produced nanoemulsions with extremely tiny and controlled droplet sizes, these components suddenly become nearly 100% bioavailable, allowing the body to absorb them much more efficiently, while the solution also becomes visibly transparent – offering heightened smell, taste, and texture benefits. An additional benefit is that the intense shear forces of UST also shred many microbial contents, providing enormously extended room temperature and cold-chain shelf life and stability for foods, beverages, and many other products.”

“Due to pressing demand, we recently decided to announce an Early Access Program for the UST platform to serve a handful of companies impatient to wait for our full commercial release planned for the 4th Quarter of 2022,” Mr. Schumacher explained. “We are choosing four to five companies over the next few weeks and months, and our team will work with them to lead the way in showing the world what we can accomplish together with our revolutionary Ultra Shear Technology platform,” he continued.

Mr. Copley focused further: “Who is Safer Medical and why did you choose them for the first customer of your UST Early Access Program?”

“Safer Medical is a small, innovative company in Montana specializing in personal care products.  It is led by a former Vietnam veteran who basically wants to give back,” shared Mr. Schumacher, adding that Safer Medical approached Pressure BioSciences with a CBD product they had designed that needed improved bioavailability. “We began with some initial demos, and then started working with them and we have dramatically improved their product by changing the formulation and making it into an immediately penetrating and highly bioavailable nanoemulsion by using Ultra Shear Technology.”

“We decided that we would bring Safer Medical on as our first customer,” continued Mr. Schumacher, “as the initial scale for this product would be a good fit with our pre-launch UST processing capacity. We’re finishing the formulation work now, and will then proceed into pilot runs, for market testing. We plan that by the fourth quarter we will start making vials for the commercial sale of this product,” he said. “We anticipate this will be the first commercial product on the market that uses Ultra Shear Technology.”

“Do you anticipate announcing any additional members for your UST Early Access Program?”, asked Mr. Copley.

“We plan to support four or five companies in the Early Access Program,” said Mr. Schumacher, adding that the Company is currently in discussions with a well-known cosmetics company, as well as companies in the agricultural, wellness, and nutraceutical spaces. “We intend on contracting with these companies in the upcoming weeks and months and expect to get several more products onto the market with UST benefits incorporated by the end of 2022.”

Mr. Schumacher concluded: “We are confident that UST will powerfully differentiate these companies’ products into leadership roles in their respective markets.  Flowing from this, our lease and license model for UST commercialization is expected to launch the revenue streams for PBI onto a dramatic new trajectory by early to mid-2023.”

To close the interview, Mr. Schumacher thanked shareholders for their support as the Company continues to close in on UST commercialization. He also encouraged listeners to keep up-to-date on the Company’s current projects and upcoming announcements.

To hear Mr. Schumacher’s entire interview, follow the link to the podcast here: https://audioboom.com/posts/8093822-pressure-biosciences-discusses-launch-of-early-access-program-for-ultra-shear-technology-for-the

 

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/

 

About Pressure BioSciences, Inc.

 

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

 

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following link:

 

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

 

Investor Contacts

 

Richard T. Schumacher, President & CEO (T) 508-230-1828

John B. Hollister, Director of Marketing and Sales (F) 508 230-1829

 

About The “Stock Day” Podcast

 

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

 

SOURCE:

Stock Day Media

(602) 821-1102